References
- Ambros, V., 2004. The functions of animal microRNAs. Nature, 431, 350–355.
- Barbarotto, E., Schmittgen, T.D., and Calin, G.A., 2008. MicroRNAs and cancer: profile, profile, profile. International journal of cancer, 122, 969–977.
- Brito, B.L., et al., 2016. Expression of stem cell-regulating miRNAs in oral cavity and oropharynx squamous cell carcinoma. Journal of oral pathology and medicine, 45, 647–654.
- Calin, G.A. and Croce, C.M., 2006. MicroRNA signatures in human cancers. Nature reviews cancer, 6, 857–866.
- Chen, X., et al., 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell research, 18, 997–1006.
- Deng, D., et al., 2016. MicroRNA-124-3p regulates cell proliferation, invasion, apoptosis, and bioenergetics by targeting PIM1 in astrocytoma. Cancer science, 107, 899–907.
- Esquela-Kerscher, A. and Slack, F.J., 2006. Oncomirs – microRNAs with a role in cancer. Nature reviews cancer, 6, 259–269.
- Fang, S., et al., 2014. Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer. Experimental and molecular pathology, 96, 438–444.
- Ferlay, J., et al., 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer, 127, 2893–2917.
- Hudcova, K., et al., 2016. Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers. Tumour biology, 37, 12627–12633.
- Humphries, B., et al., 2014. MicroRNA-200b targets protein kinase Calpha and suppresses triple-negative breast cancer metastasis. Carcinogenesis, 35, 2254–2263.
- Jemal, A., et al., 2011. Global cancer statistics. CA cancer journal for clinicians, 61, 69–90.
- Jensen, D.H., et al., 2015. Molecular profiling of tumour budding implicates TGFbeta-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma. Journal of pathology, 236, 505–516.
- Kan, C.W., et al., 2012. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC cancer, 12, 627.
- Lin, H.M., et al., 2014. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British journal of cancer, 110, 2462–2471.
- Liu, C.J., et al., 2010. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral diseases, 16, 360–364.
- Liu, C.J., et al., 2012. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head neck, 34, 219–224.
- Lo, W.L., et al., 2011. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. Journal of pathology, 223, 482–495.
- Maclellan, S.A., et al., 2012. Differential expression of miRNAs in the serum of patients with high-risk oral lesions. Cancer medicine, 1, 268–274.
- Medina-Villaamil, V., et al., 2014. Circulating microRNAs in blood of patients with prostate cancer. Actas urologicas espanolas, 38, 633–639.
- Mitchell, P. S., et al., 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the national academy of sciences U S A, 105, 10513–10518.
- Ohshima, K., et al., 2010. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS one, 5, e13247.
- Palanichamy, J.K. and Rao, D.S., 2014. miRNA dysregulation in cancer: towards a mechanistic understanding. Frontier in genetics, 5, 54.
- Peng, B., et al., 2013. MicroRNA-200b targets CREB1 and suppresses cell growth in human malignant glioma. Molecular and cellular biochemistry, 379, 51–58.
- Redova, M., Sana, J., and Slaby, O., 2013. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future oncology, 9, 387–402.
- Roush, S., and Slack, F. J., 2008. The let-7 family of microRNAs. Trends cell biology, 18, 505–516.
- Shao, N., et al., 2015. Plasma miR-454-3p as a potential prognostic indicator in human glioma. Neurological sciences, 36, 309–313.
- Shen, W., et al., 2014. MiR-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS one, 9, e86871.
- Sun, K. and Lai, E.C., 2013. Adult-specific functions of animal microRNAs. Nature reviews genetics, 14, 535–548.
- Sun, L., et al., 2012. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene, 31, 432–445.
- Tamagawa, S., et al., 2014. Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. International journal of molecular medicine, 33, 879–886.
- Wang, Q., et al., 2012. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. Journal of experimental and clinical cancer research, 31, 97.
- Xu, H., et al., 2016. Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma. Tumour biology, 37, 447–453.
- Yang, X., Ni, W., and Lei, K., 2013. miR-200b suppresses cell growth, migration and invasion by targeting Notch1 in nasopharyngeal carcinoma. Cell physiology and biochemistry, 32, 1288–1298.
- Yu, J., et al., 2014. miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1. Oncology reports, 31, 910–918.